App-Quantinova.ai

Conflicting interpretation of Genetic Variants and Cancerer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing (PROMPT)

Judith Balmana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prevalence of Clonal Hematopoiesis in Patients with Advanced Cancer

Ahmet Zehir - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Magnitude of invasive breast cancer (BC) risk associated with mutations detected by multiple-gene germline sequencing in 95,561 women.

Michael J. Hall - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

TP53

Risks of triple negative breast cancer associated with cancer predisposition gene mutations.

Fergus J. Couch - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.

Shoshana M. Rosenberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.

Kenneth Offit - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

N/A

A prospective analysis of individual body fat depots and risk of developing cancer: Insights from the Dallas heart study.

Arjun Gupta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Features of the metabolic syndrome and survival after a diagnosis of breast cancer in the Womens Health Initiative (WHI).

Jennifer Lynn Beebe-Dimmer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metabolic syndrome

N/A

Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.

Michael Francis Walsh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancer in primary immunodeficiency diseases: An analysis of cancer incidence in the United States immune deficiency network (USIDNET) registry.

Paul Mayor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of lynch syndrome (LS) in patients (pts) without prior LS-associated cancer.

Matthew B. Yurgelun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lynch syndrome

N/A

Clinical characterization of DNA mismatch repair deficiency (MMR-D) in endometrial cancer (EC).

Karen Anne Cadoo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mismatch repair deficiency

N/A

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).

Michael J. Hall - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Using a gene-environment interaction study to evaluate risk for lung cancer.

Travis John Osterman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Baseline cancer screening findings from the NCI Li-Fraumeni syndrome study.

Phuong L. Mai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Li-Fraumeni syndrome

TP53

Somatic tumor profiling of DNA mismatch repair deficient (MMR-D) colorectal cancers (CRC).

Karuna Ganesh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Tumor genomic profiling (TGP) in metastatic colorectal cancer (CRC): Bridging the community and the tertiary cancer center through genomic consultation (GC).

John M. Kaczmar - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.

Sarina Anne Piha-Paul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Variation in protein-coding sequence and the genetic basis of cisplatin-induced toxicities among testicular cancer survivors (TCS) in the Platinum Study.

Eric R Gamazon - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

Cisplatin

Contribution of the TP53 R337H mutation to the cancer burden in families with a proband with adrenocortical tumor.

Maria Jose Mastellaro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adrenal carcinoma

TP53

Filters

255783 Abstracts